Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How did dupixent's 2020 sales compare to 2019?Can i use eucerin on my dry face?Which patient groups were part of polivy's trials?How do multivitamins affect lipitor's efficacy?What's the typical lipitor rebate processing time?
See the DrugPatentWatch profile for Trintellix
What is Trintellix and when can we expect a generic version? Trintellix, also known as vortioxetine, is an antidepressant medication used to treat major depressive disorder (MDD) in adults [1]. It is an atypical antidepressant that combines the effects of a serotonin receptor modulator and a selective serotonin reuptake inhibitor (SSRI). Who makes Trintellix? Trintellix is manufactured by Lundbeck, a global pharmaceutical company based in Denmark [2]. What are the patent challenges facing generic versions of Trintellix? The patent protecting Trintellix expires in 2025 in the United States [3]. However, Lundbeck has filed patent extensions and exclusivity claims to maintain its market position. It remains to be seen whether generic manufacturers will be able to market their versions of vortioxetine before then. What is the difference between Trintellix and generic vortioxetine? If approved, generic versions of vortioxetine will be bioequivalent to Trintellix, meaning they will have the same active ingredient and pharmacokinetic profile. However, generic medications may differ in their formulation, packaging, or marketing. Can biosimilars enter the market before patent expiry? Biosimilars, also known as follow-on biologics, are not directly comparable to generic small molecule medications like vortioxetine. However, it is possible that biosimilars could be developed for other Lundbeck products in the future. What are the potential risks and side effects of Trintellix generic? As with any medication, generic vortioxetine may carry similar side effects and risks to Trintellix, including nausea, dizziness, and increased risk of bleeding [4]. Patients should consult their healthcare provider for more information. When can we expect generic versions of Trintellix to be available in the US? The FDA's approval timeline for generic vortioxetine is uncertain due to ongoing patent disputes. Once approved, generic versions will likely become available in the US shortly after the original patent expires. Sources: [1] https://www.drugpatentwatch.com/drug/Trintellix [2] https://www.lundbeck.com/ [3] https://www.drugpatentwatch.com/patent/US10912354 [4] https://www.drugs.com/vortioxetine.html
Other Questions About Trintellix :